Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 12/20 | 0.52 |
| ▸ | NPY1R | P25929 | 2/20 | 0.51 |
| ▸ | NPY2R | P49146 | 2/20 | 0.51 |
| ▸ | NPY4R | P50391 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 2/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259946 | 0.92 | GHSR (0.51) | NPBWR1NPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL30464843 | 0.91 | MC4R (0.55) | OPRM1OPRD1KISS1R | |
| SCHEMBL30259958 | 0.90 | GHSR (0.55) | NPBWR1NPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL7592892 | 0.90 | KISS1R (0.60) | KISS1R | |
| SCHEMBL30919247 | 0.90 | OPRD1 (0.57) | NPBWR1OPRM1OPRD1CCKARCCKBR | |
| SCHEMBL31680259 | 0.90 | NPBWR1 (0.60) | NPBWR1OPRM1OPRD1GHSR | |
| SCHEMBL30452155 | 0.89 | NPBWR1 (0.61) | NPBWR1 | |
| SCHEMBL29784960 | 0.88 | MC4R (0.52) | NPY1RNPY2RNPY4ROPRM1OPRD1 | |
| SCHEMBL31541507 | 0.87 | KISS1R (0.56) | OPRD1CCKARCCKBRKISS1R | |
| SCHEMBL29533726 | 0.87 | CCKBR (0.55) | NPY1RNPY2RNPY4ROPRD1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | NPBWR1 4413/4885NPY1R 2313/4885NPY2R 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.